Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Intravacc Awarded 633K CARB-X Funding | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Intravacc Awarded 633K CARB-X Funding

Aims to develop vaccine that prevents gonorrhea infections.

By: Anthony Vecchione

Intravacc, a company involved in translational research and development of preventive and therapeutic vaccines, has been awarded $633,000 from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit organization for the development of a preventive vaccine against Neisseria gonorrhoeae (NG). The vaccine will be developed on Intravacc’s outer membrane vesicle (OMV) platform technology.

The CARB-X award supports the development of Intravacc’s meningococcal outer membrane vesicle (OMV) vaccine that carries several important gonococcal antigens aimed to prevent infections by Neisseria gonorrhoeae. Through the tailored gonococcal antigens on the surface of the meningococcal OMV, Intravacc anticipates a significant enhancement in the vaccine candidate’s efficacy against gonorrhea.

Erin Duffy, R&D chief of CARB-X said, “Resistant strains of Neisseria gonorrhoeae have evaded all but one existing antibiotic (ceftriaxone), vaccines are powerful tools in the prevention of bacterial infections. With an appropriate vaccination strategy, Intravacc’s vaccine project, if successful, could prevent the disease, and significantly curb the spread of resistant bacteria across the globe.”

Jan Groen, Intravacc’s CEO, said, “This CARB-X project allows us to combine our science and OMV expertise for the development of a vaccine against gonorrhea infections. We believe the outcome of this vaccine project could be an important contribution to the worldwide antimicrobial resistance epidemic.”
https://www.intravacc.nl

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics